Acumen Pharmaceuticals (ABOS) Cash from Financing Activities (2021 - 2026)
Acumen Pharmaceuticals (ABOS) posted Cash from Financing Activities of $35.7 million for Q1 2026, up 1787000.0% sequentially from $2000.0 in Q4 2025, and up 99383.33% YoY from N/an in Q1 2025.
Acumen Pharmaceuticals (ABOS) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Cash from Financing Activities for 6 years, with the latest figure at $35.7 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 99383.33% year-over-year to $35.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.7 million (up 16725.12% YoY) and the FY2025 annual result came in at -$34000.0, down 100.49% from the prior year.
- Cash from Financing Activities climbed to $35.7 million in Q1 2026 per ABOS's latest filing, from $2000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $122.8 million in Q3 2023 and troughed at -$263000.0 in Q3 2022.
- A 5-year average of $16.5 million and a median of -$3500.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities plunged 100.51% in 2025, then surged 99383.33% in 2026.
- Over 5 years, Cash from Financing Activities stood at $4.2 million in 2022, then soared by 596.32% to $29.1 million in 2023, then plunged by 100.03% to -$9000.0 in 2024, then soared by 122.22% to $2000.0 in 2025, then surged by 1787000.0% to $35.7 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $35.7 million, $2000.0, and -$36000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | -278,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -278,000.00 |
| Jun 30, 2026 | -278,000.00 |
| Mar 31, 2026 | 35.74 Mn |
| Mar 31, 2026 | 35.74 Mn |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Mar 31, 2025 | -36,000.00 |
| Mar 31, 2025 | -36,000.00 |
| Dec 31, 2024 | -9,000.00 |
| Dec 31, 2024 | -9,000.00 |
| Sep 30, 2024 | -42,000.00 |
| Sep 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -128,000.00 |
| Jun 30, 2024 | -128,000.00 |
| Mar 31, 2024 | 7.11 Mn |
| Mar 31, 2024 | 7.11 Mn |
| Dec 31, 2023 | 29.13 Mn |
| Dec 31, 2023 | 29.13 Mn |
| Sep 30, 2023 | 122.76 Mn |
| Sep 30, 2023 | 122.76 Mn |